Akari Therapeutics PLC (ADR) - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
AKTX Nasdaq 8731 http://akaritx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Akari Therapeutics PLC (ADR)

Akari Therapeutics Announces the Appointment of Accomplished Biotech Executive Melissa Bradford-Klug as Chief Operating Officer to Lead Business Development and Company Growth Strategies - Jun 13th, 2022 11:00 am
Akari Therapeutics Presents Results from the CASCADE and CORONET Studies in COVID-19 at the American Thoracic Society (ATS) 2022 Annual Meeting - May 19th, 2022 8:05 pm
Akari Therapeutics Reports Full Year 2021 Financial Results and Highlights Clinical Progress - May 16th, 2022 10:00 am
Akari Therapeutics to Present Results from Compassionate Use of Nomacopan for COVID-19 (CORONET) and Identification of Clinical Deterioration Risk in COVID-19 (CASCADE) at the American Thoracic Society (ATS) 2022 Annual Meeting - May 11th, 2022 11:00 am
Akari Therapeutics Announces Publication of Phase II Data of Investigational Nomacopan for the Treatment of Bullous Pemphigoid (BP) in JAMA Dermatology - May 10th, 2022 11:00 am
Akari Presents Results from Two Preclinical Development Programs of Long-Acting PAS-Nomacopan in Geographic Atrophy (GA) Dry Age-Related Macular Degeneration and Nomacopan in Experimental Immune-Mediated Conjunctival Disease (EIC) - May 9th, 2022 11:00 am
Akari Therapeutics to Present on Two Ongoing Programs Covering Age-Related Macular Degeneration and Diseases of the Surface of the Eye at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting - Mar 21st, 2022 12:00 pm
Akari Therapeutics Announces New Data Supporting Use of Drug Candidate Votucalis Targeting Difficult to Treat Pain and Itch - Mar 9th, 2022 12:30 pm
Akari Therapeutics, Plc Announces $9.0 Million Registered Direct Offering - Mar 8th, 2022 4:45 pm
One Akari Therapeutics, Plc (NASDAQ:AKTX) insider upped their stake by 180% in the previous year - Mar 5th, 2022 12:02 pm
Akari Therapeutics Appoints Rachelle Jacques as President and Chief Executive Officer - Mar 2nd, 2022 12:00 pm
Akari Therapeutics Announces New Data Showing A Significant Role for Complement Activation in the Clinical Outcomes of U.S. Army Trauma Patients in Iraq and the Therapeutic Potential of Nomacopan for Treatment of Trauma - Feb 28th, 2022 2:12 pm
Akari Therapeutics to Present at BIO CEO & Investor Conference - Feb 11th, 2022 12:00 pm
Akari Advances Lung Program with Inhaled Nomacopan Focused on Early Treatment of Severe Exacerbations in Lung Diseases - Jan 26th, 2022 1:30 pm
FDA Agrees to Use of New Higher-Yielding Manufacturing Process for Nomacopan in Pivotal Clinical Studies - Jan 19th, 2022 1:30 pm
Akari Therapeutics to Present at H.C. Wainwright BioConnect Virtual Conference - Jan 4th, 2022 12:00 pm
Akari Therapeutics, Plc Announces $6.0 Million Registered Direct Offering - Dec 30th, 2021 4:03 pm
We Think Akari Therapeutics (NASDAQ:AKTX) Needs To Drive Business Growth Carefully - Dec 5th, 2021 11:13 am
Akari Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Clinical Progress - Dec 3rd, 2021 12:45 pm
Akari Therapeutics Presents New Data Revealing Potential Mechanism of Action Driving Serious Exacerbations Across Lung Disorders - Dec 1st, 2021 1:30 pm